Showing 731-740 of 1351 results for "".
- Glytone Announces Antioxidant Kit Specialhttps://practicaldermatology.com/news/20121217-glytone_announces_antioxidant_kit_special/2459657/Glytone currently offers two limited-edition antioxidant kits, featuring a selection of three products from the Glytone antioxidant range. One version includes Anti-aging Serum, Anti-aging Cream, and Anti-aging Eye Cream while the other featur
- ISHRS Kicks Off 20th Anniversaryhttps://practicaldermatology.com/news/20121003-ishrs_kicks_off_20th_anniversary/2459716/The International Society of Hair Restoration Surgery kicks off its 20th Anniversary this month. The ISHRS Annual Scientific Meeting is October 17-20 at Atlantis, Paradise Island, the Bahamas. The society is highlighting follicular units in hair res
- Kythera Initiates Phase 3 trials for Investigational Injectablehttps://practicaldermatology.com/news/20120320-kythera_initiates_phase_3_trials_for_investigational_injectable/2459841/Kythera Biopharmaceuticals has initiated two Phase 3 trials of ATX-101, a first-in-class injectable drug under clinical investigation for the reduction of submental fat. The Phase 3 trials, known as REFINE-1 and REFINE-2 (Randomized Doubl
- Onset Launches Aurstat Kithttps://practicaldermatology.com/news/20120302-onset_launches_aurstat_kit/2459855/The Aurstat Kit (Onset Dermatologics) containing Aurstat Skin and Wound Hydrogel and HylatopicPlus Cream is now available. Aurstat is an easy to use topical formulation, the company says. HylatopicPlus is a ceramide-rich, non-steroidal prescription t
- Early Data Presented for Celotres™ for Keloid Scarshttps://practicaldermatology.com/news/20120224-early_data_presented_for_celotres_for_keloid_scars/2459866/Results from Halscion, Inc.'s KLEAR Study, which evaluated the initial safety and efficacy of Celotres™ in the treatment of keloid scars adjunctive to surgical excision, show a significant reduction (p=0.0110) in keloid recurrence, as compared to scientific literature, following a single treatment o
- Study: TPC2 Ion Channel Key Driver of Melanoma Progressionhttps://practicaldermatology.com/news/study-tpc2-ion-channel-key-driver-melanoma-progression/2468665/New research has succeeded in identifying a critical regulator of melanoma progression. The research, published by a group from Ludwig-Maximilians-Universität München in Nature Communications, highlights how TPC2 influences intracellular trafficking pathways that drive melanoma c
- Panel Agrees on Key Recommendations for Oral Minoxidil Usehttps://practicaldermatology.com/news/panel-agrees-key-recommendations-oral-minoxidil-use/2468659/A new international consensus statement offers guidance on the off-label use of low-dose oral minoxidil (LDOM) for managing hair loss. The
- Study Identifies Key Patient-Centered Attributes of Atopic Dermatitis Flarehttps://practicaldermatology.com/news/study-identifies-key-patient-centered-attributes-ad-flare/2468156/A new study revealed a consensus on the patient-centered definition of an atopic dermatitis (AD) flare. Researchers for the study recruited 26 participants for focus groups and 631 participants for a survey through the National Eczema Association. The participants rated various attributes
- Panel IDs Key Skincare Strategies for Adult Acnehttps://practicaldermatology.com/news/dermatologists-identify-key-skincare-strategies-adult-acne/2467834/New research featuring input from an expert acne panel emphasized the critical importance of skin care in managing adult acne. The panel, consisting of eight dermatologists, looked at the role of skin barrier function in adult acne and the benefits of adjunctive skin care, such as cleanse
- Nemolizumab Meets Key Endpoints in ARCADIA Studieshttps://practicaldermatology.com/news/nemolizumab-meets-key-endpoints-arcadia-studies/2467533/Nemolizumab, a monoclonal antibody targeting the IL-31 receptor, showed efficacy for the treatment of atopic dermatitis, particularly pruritus and sleep disturbance, according to an announcement from Galderma. The full results of the phase III ARCADIA 1 and 2 trials for nemolizumab were pu